April 28, 2017

Exactech, Inc.
Patrick Hughes
Senior Regulatory Affairs Specialist
2320 NW 66th Court
Gainesville, Florida 32653

Re: K171045
Trade/Device Name: Exactech® Truliant™ Line Extensions
Regulation Number: 21 CFR 888.3560
Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis
Regulatory Class: Class II
Product Code: JWH
Dated: April 6, 2017
Received: April 7, 2017

Dear Mr. Hughes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR
Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Vincent J. Devlin -S

for

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
Draft

Indications for Use

510(k) Number (if known)
K171045

Device Name
Exactech® Truliant™ Line Extensions

Indications for Use (Describe)

The TRULIANT Femoral Components, Tibial Inserts, and Tibial Trays are indicated for use in skeletally mature individuals undergoing primary surgery for total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-traumatic degenerative problems. They are also indicated for revision of failed previous reconstructions where sufficient bone stock and soft tissue integrity are present.

The TRULIANT Femoral Components, Tibial Inserts, and Tibial Trays are indicated for cemented use only.

Type of Use (Select one or both, as applicable)

- [ ] Prescription Use (Part 21 CFR 801 Subpart D)
- [ ] Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

*An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.*
**Exactech® Truliant™ Line Extensions**  
**Special 510(k) – 510(k) Summary of Safety and Effectiveness**

**Sponsor:**  
Exactech, Inc.  
2320 N.W. 66th Court  
Gainesville, FL 32653

Phone: (352) 377-1140  
Fax: (352) 378-2617

FDA Establishment Number 1038671

**Contact:**  
Patrick Hughes  
Senior Regulatory Affairs Specialist

**Date:**  
April 6, 2017

**Trade or Proprietary or Model Name(s):**  
Exactech® Truliant™ Line Extensions

**Common Name:**  
Cemented Total Knee Prosthesis

**Classification Name:**  
Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer/Metal/Polymer

**Product Code:**  
JWH

**Classification Panel:**  
Orthopedic

**Regulation Number**  
888.3560

**Device Class**  
II

**Information on devices to which substantial equivalence is claimed:**

<table>
<thead>
<tr>
<th>510(k) Number</th>
<th>Trade or Proprietary Model Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>K170240</td>
<td>Exactech Truliant Femoral Components</td>
<td>Exactech, Inc</td>
</tr>
<tr>
<td>K152170</td>
<td>Exactech One Logic Tibial Assembly</td>
<td>Exactech, Inc</td>
</tr>
</tbody>
</table>

**Indications for Use:**  
The TRULIANT Femoral Components, Tibial Inserts, and Tibial Trays are indicated for use in skeletally mature individuals undergoing primary surgery for total knee replacement due to osteoarthritis, osteonecrosis, rheumatoid arthritis and/or post-
traumatic degenerative problems. They are also indicated for revision of failed previous reconstructions where sufficient bone stock and soft tissue integrity are present.

The TRULIANT Femoral Components, Tibial Inserts, and Tibial Trays are indicated for cemented use only.

Device Description:
Truliant femoral components are for use in resurfacing femoral bone as part of tri-compartmental total knee arthroplasty employing modular components from the Optetrak / Optetrak Logic and Truliant device families.

Proposed Truliant femoral components represent modifications to Truliant femoral components cleared per 510(k) K170240. The proposed Truliant femoral components are identical to cited predicate femoral components except for dimensional modifications representing new additions to the product scope.

Proposed Truliant tibial trays represent modifications to One Logic tibial trays cleared per 510(k) K152170 and rebranded as Truliant per 510(k) K170240. The proposed Truliant trays are identical to cited predicate trays except for dimensional modifications representing new additions to the product scope.

Proposed Truliant tibial inserts represent modifications to One Logic tibial inserts cleared per 510(k) K152170 and rebranded as Truliant per 510(k) K170240. The proposed Truliant inserts are identical to cited predicate inserts except for dimensional modifications representing new additions to the product scope.

The proposed devices operate using the same fundamental scientific technology, have the same intended use and design features, employ the same materials of construction, are offered in the same product size scopes, and are implanted using a similar surgical technique and the same or similar instrumentation. The only modifications proposed by this submission are dimensional.
Testing Description:
This submission references results for mechanical patellofemoral constraint, patellofemoral contact pressure testing, mechanical insert / tray assembly micromotion, mechanical insert / tray locking strength, and device biocompatibility. Results conclude the proposed Truliant devices do not represent a new worst-case for risks associated with patellofemoral contact, insert / tray assembly properties, or biocompatibility.

Pyrogen testing was conducted in accordance with USP <161>, USP <85>, and ANSI/AAMI ST72 to ensure the proposed Truliant components meet recommended limits per FDA’s Guidance Document Submission and Review of Sterility Information in Premarket (510(k)) Submission for Devices Labeled as Sterile.

Substantial Equivalence Conclusion:
Results of engineering studies referenced in this 510(k) submission demonstrate proposed Truliant line extensions are substantially equivalent to cited cleared predicate Truliant femoral components and One Logic / Truliant tibial inserts and tibial trays.